- Wildfire Survivors Still Struggle With Basic Needs and Support
- Trump Administration Plans Deep Cuts to Federal Health Budget
- Top NIH Nutrition Researcher Quits, Citing Censorship Under Kennedy
- HHS Fires Team That Sets Federal Poverty Guidelines
- First Weight-Loss Pill From Lilly Shows Promising Results
- Allergy Expert Gives Tips On Seasonal Allergies
- Pregnancy Complications Affect Future Heart Health
- Stroke Among Younger Adults Linked To Non-Traditional Risks
- Psoriatic Arthritis Diagnoses Are Lagging, Patients Undertreated
- Magnetic Stimulation Aids Speech Recovery Following Stroke
Orbactiv Approved for Drug-Resistant Skin Infections

The antibacterial drug Orbactiv (oritavancin) has been approved by the U.S. Food and Drug Administration to treat drug-resistant skin infections in adults, the agency said in a news release.
The drug is sanctioned to treat methicillin-resistant Staphylococcus aureus (MRSA) and other acute bacterial skin infections. It’s the third such drug approved in 2014, following May approval of Dalvance (dalbavancin) and June approval of Sivextro (tedizolid), the FDA said.
Orbactiv’s safety and effectiveness were evaluated in two clinical studies involving almost 2,000 adults. The most common side effects included headache, nausea, vomiting, skin abscesses on the arms and legs, and diarrhea.
The drug’s label will include a boxed warning that it could interact with the blood-thinning medication warfarin, the agency said.
Orbactiv is marketed by The Medicines Company, based in Parsippany, N.J.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.